Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) reached a new 52-week low during mid-day trading on Friday. The stock traded as low as $34.00 and last traded at $34.00, with a volume of 2,132 shares trading hands. The stock had previously closed at $34.16.
Wall Street Analyst Weigh In
A number of analysts have commented on ZLDPF shares. Wells Fargo & Company reissued an “overweight” rating on shares of Zealand Pharma A/S in a report on Thursday, August 13th. Jefferies Financial Group cut Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. Zacks Research upgraded Zealand Pharma A/S from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 12th. Finally, Barclays downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 8th. Two analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and eight have given a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold”.
Read Our Latest Analysis on ZLDPF
Zealand Pharma A/S Price Performance
The business’s 50 day moving average price is $44.46 and its 200 day moving average price is $45.90. The stock has a market capitalization of $2.43 billion, a P/E ratio of 5.64 and a beta of 0.95. The company has a debt-to-equity ratio of 0.02, a current ratio of 13.98 and a quick ratio of 13.98.
Zealand Pharma A/S Company Profile
Zealand Pharma A/S is a biotechnology company headquartered in Denmark that discovers, develops and commercializes peptide-based medicines. Its research focuses primarily on metabolic and gastrointestinal diseases, including obesity, diabetes and rare disorders. The company develops therapies designed to address significant unmet medical needs through its expertise in peptide chemistry and drug delivery.
Zealand’s marketed product portfolio includes Zegalogue (dasiglucagon), an emergency treatment for severe hypoglycemia in people with diabetes.
Further Reading
- Five stocks we like better than Zealand Pharma A/S
- Rocket Lab’s Neutron Delay Leaves Wall Street Bullish But Raises the Stakes for 2027
- ManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay Solid
- Does the AI Selloff Put Alphabet’s Breakout in Doubt?
- Bank Earnings Are Mixed—These 2 ETFs Offer Very Different Paths to a Recovery
Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.
